Results 211 to 220 of about 785,669 (310)
Microfluidics Lab‐on‐a‐Chip Approaches to Decipher Atherosclerosis Pathogenesis
Figure created with BioRender.com. This review highlights how microfluidic lab‐on‐a‐chip models recreate key features of atherosclerosis in controlled, human‐relevant environments. It summarizes advances in modeling endothelial dysfunction, immune cell recruitment, foam cell formation, vascular remodeling, stenosis, and plaque rupture.
Fahima Akther, Hang Thu Ta
wiley +1 more source
Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins. [PDF]
Spidel JL +8 more
europepmc +1 more source
HER2‐targeted AIE780‐A1811 nanoparticles self‐assemble via amide coupling of a mitochondria‐directed photosensitizer with the ADC SHR‐A1811. Upon 660 nm irradiation, they generate ROS, photothermal effects, and controlled drug release, inducing immunogenic pyroptosis and M2‐to‐M1 macrophage reprogramming. This dual action remodels the immunosuppressive
Xiaohong Liu +12 more
wiley +1 more source
Biomaterial platforms can control where and when mRNA‐encoded proteins are expressed to support tissue repair. This Review proposes a cargo–target–timing framework linking therapeutic function, target tissues and cells, and expression profiles with carrier and scaffold design.
Huachun Pan +14 more
wiley +1 more source
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou +4 more
wiley +1 more source
ABSTRACT Objective Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition often associated with other type‐2 diseases. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has revolutionized the treatment of severe CRSwNP.
Pietro Orlando +17 more
wiley +1 more source
Xenotransplantation at a Crossroads: Breakthroughs, Challenges, and the Path Forward
Organ Medicine, EarlyView.
Xiaoyu Gan +3 more
wiley +1 more source
ABSTRACT Vunakizumab is a humanized anti‐IL‐17A monoclonal antibody approved in China for moderate‐to‐severe plaque psoriasis. Real‐world data on its effectiveness and predictors of response remain scarce. This prospective, single‐center, observational study enrolled 34 adults receiving vunakizumab (240 mg subcutaneously at weeks 0, 2, and 4, then ...
Tong Wu +4 more
wiley +1 more source
This meta‐analysis of 18 studies (3962 patients) demonstrates that nimotuzumab combined with chemoradiotherapy significantly improves overall survival and progression‐free survival in locally advanced head and neck squamous cell carcinoma, without increasing severe toxicity.
Chengzheng Bao +6 more
wiley +1 more source
PRL3-zumab, a first-in-class humanized antibody for cancer therapy. [PDF]
Thura M +23 more
europepmc +1 more source

